GlassScriptPhysician profile
Syeda Ameena
NPI 1972998706
$837.86
in general payments reported to CMS, 2019-2025
14 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.29 · 2022: $138 · 2023: $163 · 2024: $311 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.91 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $153.62 | 2023-2025 | |
| Amgen INC. | $146.18 | 2023-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $115.42 | 2024 | Ozempic, Rybelsus |
| Phadia US INC. | $86.28 | 2022-2024 | Immunocap |
| Hologic Sales and Service, LLC | $73.96 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Mallinckrodt Hospital Products INC. | $61.94 | 2022 | |
| Sanofi-Aventis U.S. LLC | $37.83 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.50 | 2022 | |
| Lilly USA, LLC | $27.12 | 2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.75 | 2022 | |
| Sanofi Pasteur INC. | $22.38 | 2025 | |
| Cranial Technologies, INC | $19.59 | 2025 | Doc Band |
| Pfizer INC. | $18.04 | 2021 | |
| Qiagen, LLC | $17.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syeda Ameena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.